Search

Displaying results 2881 - 2890 of 10000 in total
  1. Drug

    NV-52

    go.drugbank.com/drugs/DB05673
    Experimental

    NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.

  2. Drug

    Plerixafor

    go.drugbank.com/drugs/DB06809
    ApprovedInvestigational

    [A7117] Compared to placebo with G-CSF, the plerixafor and G-CSF mobilization regimen has a higher probability of achieving the optimal CD34+ cell target for tandem transplantation in fewer apheresis procedures … Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer.

    Products: Mozobil 20 mg/ml solution for injection, Mozobil Solution for Injection 20mg/ml
  3. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    [L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor.

    Products: Benlysta Powder for Solution for Infusion 400mg, Benlysta Powder for Solution for Infusion 120mg
  4. Drug

    Butorphanol

    go.drugbank.com/drugs/DB00611
    ApprovedIllicitVet approved

    A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.

    Categories: Heterocyclic Compounds with 4 or More Rings
  5. Drug

    Technetium Tc-99m tilmanocept

    go.drugbank.com/drugs/DB09266
    Approved

    DTPA serves as a chelating agent for technetium Tc 99m to bind [FDA Label]. … Food and Drug Administration (FDA) for the imaging of lymph nodes with or without scintigraphic imaging.

    Products: Kit for the preparation of Lymphoseek (technetium Tc 99m tilmanocept)
  6. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    history of exacerbations), and NCT06040086 (recruiting; symptomatic COPD with a history of exacerbations). … NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in COPD patients with a

    Categories: Experimental Unapproved Treatments for COVID-19
  7. Drug

    Didesmethylrocaglamide

    go.drugbank.com/drugs/DB15496
    Experimental

    Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus _Aglaia_. … [A186760] While traditionally used for their insecticidal benefits,[A186796] this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas

  8. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.

  9. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency. … Cerliponase alfa is a hydrolytic lysosomal N-terminal tripeptidyl peptidase-1 (TPP1).

  10. Drug

    Zapomeran

    go.drugbank.com/drugs/DB21761
    Approved

    Zapomeran, marketed under the brand name Kostaive (ARCT-154), is a self-amplifying mRNA COVID-19 vaccine for individuals 18 years and older. … Self-amplification allows for the use of lower doses while providing higher immunogenicity compared to a conventional mRNA COVID-19 vaccine.